BiotechTube
Flashpoint Therapeutics

Flashpoint Therapeutics

Cambridge, United States· Est.
flashpoint.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Flashpoint Therapeutics is a private, clinical-stage biotech leveraging a nanotechnology platform pioneered in Chad Mirkin's lab to create targeted, multi-component nanomedicines. Its platform, validated in vivo and with an IND-cleared candidate, demonstrates significant improvements in potency, delivery, and stability across various therapeutic modalities, including cancer immunotherapy. The company is advancing an internal pipeline while seeking strategic partnerships to develop best-in-class RNA and peptide therapeutics.

OncologyGenetic DiseasesNeurological Disorders

Technology Platform

Proprietary nanotechnology platform for designing precision-engineered structural nanomedicines that co-deliver optimized combinations of nucleic acids (mRNA, DNA, CRISPR), peptides, and small molecules with controlled stoichiometry, architecture, and activation kinetics to target cells.

Funding History

1
Total raised:$10M
Seed$10M

Opportunities

The platform's ability to co-deliver multiple therapeutic payloads with precision addresses a major unmet need in oncology and genetic medicine, opening large markets.
Demonstrated blood-brain barrier penetration creates a unique opportunity in the valuable and challenging CNS disorder therapeutic area.
The modular nature of the technology enables rapid, partnership-driven expansion into new disease areas and modalities.

Risk Factors

The novel and complex nanostructures face significant translational risk, including potential manufacturing scalability challenges and unforeseen safety or efficacy issues in human trials.
The company operates in a highly competitive drug delivery landscape against well-funded alternatives.
As a pre-revenue, private company, it is dependent on securing additional financing to advance its pipeline to key value-inflection points.

Competitive Landscape

Flashpoint competes in the advanced drug delivery space against companies developing next-generation lipid nanoparticles (LNPs), viral vectors, and other nanocarriers from firms like Moderna, BioNTech, and Arcturus, as well as biotechs like ReCode Therapeutics and Entos Pharmaceuticals. In cancer immunotherapy, it faces competition from all major pharma companies and biotechs developing combination therapies. Its key differentiator is the precise architectural control and multi-component co-delivery within a single, tunable nanostructure.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →